GW Pharmaceuticals (Jazz Pharmaceuticals)
About GW Pharmaceuticals (Jazz Pharmaceuticals)
GW Pharmaceuticals, now part of Jazz Pharmaceuticals, is the world's leading cannabinoid pharmaceutical company and creator of Epidiolex, the first FDA-approved plant-derived cannabinoid medicine. Based in Cambridge, UK, GW pioneered the development of prescription cannabinoid medicines through rigorous clinical trials. The company's Epidiolex is approved for treating severe forms of epilepsy including Dravet and Lennox-Gastaut syndromes.
Key Facts
- 1Created Epidiolex, the first FDA-approved plant-derived cannabinoid medicine
- 2Acquired by Jazz Pharmaceuticals for USD 7.2 billion in 2021
- 3Epidiolex generates over USD 700 million in annual revenue
- 4Sativex is approved in over 25 countries for multiple sclerosis spasticity
Frequently Asked Questions
What is Epidiolex used for?
Epidiolex is a purified cannabidiol (CBD) oral solution approved by the FDA and EMA for treating seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex in patients one year of age and older.
Is GW Pharmaceuticals still an independent company?
No, GW Pharmaceuticals was acquired by Jazz Pharmaceuticals in 2021 for approximately USD 7.2 billion. Its cannabinoid medicines, including Epidiolex and Sativex, are now part of Jazz's neuroscience portfolio.
More Cannabis Companies in Cambridge
Cannabis Laws
Products
- Epidiolex (cannabidiol oral solution)
- Sativex (nabiximols oromucosal spray)
- Pipeline cannabinoid medicines
Specialties
Company Details
- Type
- Medical & Pharma
- Location
- Cambridge, United Kingdom
- Founded
- 1998
- Publicly Traded
- Yes
- Ticker
- NASDAQ:JAZZ